Literature DB >> 20591500

Aberrant autophosphorylation of c-Kit receptor in canine mast cell tumor cell lines.

Yoshinori Takeuchi1, Yasuhito Fujino, Manabu Watanabe, Takayuki Nakagawa, Koichi Ohno, Nobuo Sasaki, Sumio Sugano, Hajime Tsujimoto.   

Abstract

Several studies indicated that KIT mutation could cause ligand-independent activation of c-Kit receptor in canine mast cell tumor (MCT). The objective of this study was to investigate mechanisms of c-Kit receptor activation in various canine MCT cell lines. Four cell lines, HRMC (derived from cutaneous MCT), VIMC1 (visceral MCT), CoMS1 (visceral MCT) and CMMC1 (cutaneous MCT), were cultured in stem cell factor (SCF, a ligand of c-Kit receptor)-free medium and subjected to analyses of KIT mutation, c-Kit receptor phosphorylation, SCF expression and the effects of SCF stimulation. In addition, the SCF/c-Kit receptor autocrine mechanism was verified in HRMC cells. HRMC cells expressed wild type c-Kit receptor. Both VIMC1 and CoMS1 cells had the same one amino acid (AA) substitution in the extracellular domain of c-Kit receptor. CMMC1 cells had at least three variants of c-Kit receptor such as one AA deletion in the extracellular domain (variant A), one AA substitution in the extracellular domain as well as an internal tandem duplication in the juxtamembrane domain (variant B), and a nonsense mutation (variant C). Both mature and immature forms of c-Kit receptor were observed and the c-Kit receptors were phosphorylated in all cell lines. While both mature and immature forms of c-Kit receptor were substantially phosphorylated in CMMC1 cells, the immature form was slightly phosphorylated in other cell lines. Phosphorylation of c-Kit receptor in HRMC, VIMC1 and CoMS1 cells were enhanced by SCF stimulation whereas no enhancement was observed in CMMC1 cells. There was no effect of SCF stimulation on proliferation of all the cell lines. SCF protein was detectable in only HRMC cells although mRNA expression of SCF was detected in all the cell lines. A tyrosine kinase inhibitor Dasatinib (internal inhibitor) inhibited c-Kit receptor phosphorylation in HRMC cells whereas anti-canine SCF antibody (external inhibitor) had no inhibitory effect. Thus there could be no external SCF/c-Kit receptor autocrine mechanism whereas there could be an internal autocrine mechanism within HRMC cells. The results indicated that consistent c-Kit receptor phosphorylation could be caused by the stimulation with autocrine SCF in HRMC cells while it could be caused by functional mutations of KIT in VIMC1, CoMS1 and CMMC1 cells. As the four canine MCT cell lines had various aberrations associated with c-Kit receptor phosphorylation, KIT mutation and SCF expression, such molecular biological diversity might reflect the different biological behavior in canine MCT. (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591500     DOI: 10.1016/j.vetimm.2010.05.009

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

1.  The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.

Authors:  K Shiomitsu; E Sajo; C Rubin; I Sehgal
Journal:  Vet Comp Oncol       Date:  2013-06-13       Impact factor: 2.613

2.  c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies.

Authors:  Rosa Patruno; Ilaria Marech; Nicola Zizzo; Michele Ammendola; Patrizia Nardulli; Claudia Gadaleta; Marcello Introna; Gennaro Capriuolo; Rosa Angela Rubini; Domenico Ribatti; Cosmo Damiano Gadaleta; Girolamo Ranieri
Journal:  Biomed Res Int       Date:  2014-05-12       Impact factor: 3.411

3.  Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation.

Authors:  Mitsuhiro Irie; Yoshinori Takeuchi; Yuzo Ohtake; Hitomi Suzuki; Nao Nagata; Takuma Miyoshi; Yumiko Kagawa; Tetsushi Yamagami
Journal:  J Vet Med Sci       Date:  2015-06-12       Impact factor: 1.267

4.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

5.  Dermal Extracellular Matrix-Derived Hydrogels as an In Vitro Substrate to Study Mast Cell Maturation.

Authors:  Emily W Ozpinar; Ariana L Frey; Greer K Arthur; Camilo Mora-Navarro; Andreea Biehl; Douglas B Snider; Glenn Cruse; Donald O Freytes
Journal:  Tissue Eng Part A       Date:  2020-11-19       Impact factor: 4.080

6.  Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.

Authors:  Eleonora Zorzan; Katia Hanssens; Mery Giantin; Mauro Dacasto; Patrice Dubreuil
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.